19/05/2021 - General information
The consultant in the Pneumology Department at Hospital del Mar and Hospital del Mar Medical Research Institute researcher will be at the helm of this prestigious publication for the next three years. Dr. Esther Barreiro, a consultant in the Pneumology Service at Hospital del Mar and coordinator of the IMIM's Research Group on Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer, will be the new editor-in-chief of ERJ Open Research, the official journal of the European Respiratory Society (ERS). Her appointment was announced at the last meeting of the ERS Executive Committee and will take effect in January 2022.
17/05/2021 - General information
The head of the Medical Oncology Service and director of the Cancer Research Programme at the Hospital del Mar Medical Research Institute is one of the most outstanding specialists among Catalan oncologists. The Governance and Economics Coordinates Institute has just published its TOP 100 ranking of the best doctors working in Catalan hospitals, both public and private. Dr. Joan Albanell, head of the Medical Oncology Department at Hospital del Mar, features among the top ten specialists in the oncology section.
13/05/2021 - Press release
Hospital del Mar-IMIM is leading an international clinical trial to evaluate the performance and suitability of new equipment for locating the sentinel lymph node in prostate cancer patients. The new tool is a flexible, miniaturized probe, which should improve the detection of a marker (a radioactive molecule) injected into the patient to locate the first node the tumour drains to. The technology SENSEI®, has been developed by the UK company Lightpoint Medical with the support of the Hospital del Mar Urology Service.
12/05/2021 - General information
Montagut has been invited to be part of the group of experts who will draft the European Society of Medical Oncology recommendations on the appropriate use of this technique and its implementation in clinical practice. The head of the Digestive Oncology section in the Medical Oncology Service at Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute (IMIM), Dr. Clara Montagut, will be a co-author of the ESMO recommendations for the use of liquid biopsy in cancer patients. The project is led by Professor Nicholas Turner, from the Institute of Cancer Research in London. The initiative is one of the tasks of the organisation's Translational Research and Precision Medicine Working Group.
07/05/2001 - Institutional news
Researcher Camille Lassale from the IMIM Cardiovascular Epidemiology and Genetics Research Group has obtained one of the 15 "Junior Leader Fellowship - Retaining" grants from the La Caixa Foundation to study the impact of nutrition on epigenetic markers. This call is very competitive; of the 399 applications received, only 15 researches have been awarded throughout Spain and Portugal, and of these 15, there are only four women. The Junior Leader Fellowships postdoctoral research program aims to hire excellent researchers of any nationality who wish to continue their research career in Spain or Portugal. The objectives of this program are to promote innovative and high-quality research in Spain and Portugal and support the best scientific talent by providing them with a competitive and attractive environment in which to conduct excellent research.
05/05/2021 - General information
The General Assembly of the ISCIII Clinical Research Support Platform has elected Dr. Ana Aldea, Head of the Clinical Pharmacology Section at Hospital del Mar and coordinator of the IMIM Clinical Research Unit, as a member of the Steering Committee. The ISCIII Clinical Research Support Platform, (SCReN, Spanish Clinical Research Network), is a network structure supporting clinical research and is made up of the 34 units financed in the PT20 call of the Carlos III Health Institute, distributed among hospitals throughout the National Health System (SNS). This network structure, acting in a coordinated manner, will be responsible for executing the actions necessary to achieve the Platform's objectives.
03/05/2021 - Institutional news
Dr. Antonio García de Herreros, a researcher at the Hospital del Mar Medical Research Institute (IMIM) and professor in the Department of Experimental and Health Sciences at Pompeu Fabra University, has joined the Appeals Committee for the Quality Agency of the Catalan University System (AQU Catalunya), the main instrument for promoting and assessing quality in Catalan universities.
29/04/2021 - General information
The benchmark meeting in the field of immunotherapy cancer treatment was held once again, on April 9, in a hybrid format. This year, the presentations focused on the research and development of this type of treatment for various types of tumours, as well as molecular diagnostics. Understanding which factors make immunotherapy work in some cancer patients and not in others, the structure and genetics of tumours to help select the most appropriate treatment, is the current focus of research in this field. This was evident at the new edition of the Optimizing Immunotherapy, New Approaches, Biomarkers, Sequences and Combinations congress, held on 9 April in a hybrid format and organised by the Hospital del Mar Medical Research Institute (IMIM) and Hospital del Mar. The meeting brought together around twenty of the world's leading experts in research and clinical application of immunotherapy treatments to analyse the latest breakthroughs and the future of immunotherapy. It was backed by the SEOM, SOGUC and CIBERONC.
Més informació "The future of immunotherapy at the Optimizing Immunotherapy Congress"
28/04/2021 - General information
The head of the Epilepsy Unit at Hospital del Mar and coordinator of the Epilepsy Research Group at the Hospital del Mar Medical Research Institute has been appointed Spanish Society of Neurology representative in the field of epilepsy to the top European scientific body in the field of neurology.
23/04/2021 - General information
In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven de novo drug design methods in collaboration with Gaylan Bio to rapidly design novel molecules which would bind to the previously 'undruggable' Huntington's Disease target. Huntington's Disease (HD) is a neurodegenerative disorder that affects thousands of patients worldwide. There is currently no cure or disease modifying treatment for HD. This is why US-based company Galyan Bio and Barcelona-based Chemotargets joined efforts to design a first in class drug for HD. The result has been the generation of a first-in-class drug candidate for HD. Galyan Bio plans to start clinical trials in HD in 2022. Galyan Bio's new treatment is intended to slow down the disease in symptomatic patients and delay manifestation of HD in symptom-free gene carriers.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact